Elan: CHMP Adopts Negative Opinion on Appeal for Natalizumab

Elan Corp. said that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease.
MarketWatch